| Indicators | Browse All

Precigen, Inc. (PGEN)

Healthcare | Biotechnology | Germantown, United States | NasdaqGS
5.12 USD -0.05 (-0.967%) ⇩ (July 14, 2026, 4 p.m. EDT)

Short-term:★★★⯪☆Long-term:★⯪☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:42 a.m. EDT

The immediate outlook is driven by aggressive speculative positioning rather than fundamental stability. While the stock has recently rallied off multi-year lows, the underlying business remains deeply distressed with negative gross margins, negative operating cash flow, and a massive debt load relative to equity. The market is pricing in a potential turnaround or catalyst, as shown by the heavy call volume, but the fundamentals—specifically the inability to generate profit or free cash flow—remain a severe drag on long-term value. This creates a high-risk scenario where the stock could surge on news but lacks the operational foundation to sustain a higher valuation without significant restructuring or capital infusion.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.059785
AutoARIMA0.070681
AutoETS0.071374
MSTL0.078472

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 28%
H-stat 24.77
Ljung-Box p 0.000
Jarque-Bera p 0.584
Excess Kurtosis 0.76
Attribute Value
Sector Healthcare
Debt to Equity Ratio 485.545
Revenue per Share 0.096
Market Cap 1,825,336,192
Forward P/E -23.27
Beta 1.01
Website https://precigen.com

As of July 11, 2026, 6:42 a.m. EDT: Speculators are heavily positioning for upside, evidenced by massive open interest in out-of-the-money calls (strikes $7.50 and $10.00) compared to negligible put volume. The call chain shows significant concentration in strikes well above the current price, while put activity is minimal and focused on deep out-of-the-money levels, indicating a speculative bet on a significant rally rather than a hedge against downside.


Info Dump

Attribute Value
52 Week Change 1.7826087
Address1 20,374 Seneca Meadows Parkway
All Time High 68.83053
All Time Low 0.65
Ask 5.13
Ask Size 1
Audit Risk 5
Average Daily Volume10 Day 4,539,020
Average Daily Volume3 Month 4,492,155
Average Volume 4,492,155
Average Volume10Days 4,539,020
Beta 1.005
Bid 4.42
Bid Size 1
Board Risk 7
Book Value 0.057
City Germantown
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 5.12
Current Ratio 4.818
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 5.22
Day Low 5.0
Debt To Equity 485.545
Display Name Precigen
Earnings Call Timestamp End 1,778,704,200
Earnings Call Timestamp Start 1,778,704,200
Earnings Timestamp 1,778,702,400
Earnings Timestamp End 1,786,478,400
Earnings Timestamp Start 1,786,478,400
Ebitda -86,329,000
Ebitda Margins -2.73236
Enterprise To Ebitda -21.631
Enterprise To Revenue 59.102
Enterprise Value 1,867,340,160
Eps Forward -0.22
Eps Trailing Twelve Months -1.2
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.6318
Fifty Day Average Change 0.4881997
Fifty Day Average Change Percent 0.105401725
Fifty Two Week Change Percent 178.26088
Fifty Two Week High 6.04
Fifty Two Week High Change -0.9200001
Fifty Two Week High Change Percent -0.1523179
Fifty Two Week Low 1.47
Fifty Two Week Low Change 3.6499999
Fifty Two Week Low Change Percent 2.4829931
Fifty Two Week Range 1.47 - 6.04
Financial Currency USD
First Trade Date Milliseconds 1,375,968,600,000
Float Shares 189,660,276
Forward Eps -0.22
Forward P E -23.272726
Free Cashflow -90,111,504
Full Exchange Name NasdaqGS
Full Time Employees 160
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins -0.35384998
Gross Profits -11,180,000
Has Pre Post Market Data 1
Held Percent Insiders 0.13706
Held Percent Institutions 0.71219003
Implied Shares Outstanding 356,510,980
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Long Name Precigen, Inc.
Market us_market
Market Cap 1,825,336,192
Market State PRE
Max Age 86,400
Message Board Id finmb_22365961
Most Recent Quarter 1,774,915,200
Net Income To Common -383,417,984
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,846,726,876
Number Of Analyst Opinions 2
Open 5.18
Operating Cashflow -115,333,000
Operating Margins -0.25778
Overall Risk 6
Payout Ratio 0.0
Phone 301 556 9900
Pre Market Change -0.03999996
Pre Market Change Percent -0.7812493
Pre Market Price 5.08
Pre Market Time 1,784,113,213
Previous Close 5.17
Price Hint 2
Price To Book 89.82456
Price To Sales Trailing12 Months 57.772945
Profit Margins 0.0
Quick Ratio 3.931
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.05000019
Regular Market Change Percent -0.96712166
Regular Market Day High 5.22
Regular Market Day Low 5.0
Regular Market Day Range 5.0 - 5.22
Regular Market Open 5.18
Regular Market Previous Close 5.17
Regular Market Price 5.12
Regular Market Time 1,784,059,200
Regular Market Volume 2,904,684
Return On Assets -0.42069
Return On Equity -11.454229
Revenue Growth 16.339
Revenue Per Share 0.096
Sand P52 Week Change 0.2043345
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 3
Shares Outstanding 356,510,980
Shares Percent Shares Out 0.124
Shares Short 44,222,506
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 40,254,841
Short Name Precigen, Inc.
Short Percent Of Float 0.2283
Short Ratio 7.48
Source Interval 15
State MD
Symbol PGEN
Target High Price 13.9
Target Low Price 11.0
Target Mean Price 12.45
Target Median Price 12.45
Total Cash 56,246,000
Total Cash Per Share 0.158
Total Debt 98,250,000
Total Revenue 31,595,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.2
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.1426
Two Hundred Day Average Change 0.9773998
Two Hundred Day Average Change Percent 0.23593874
Type Disp Equity
Volume 2,904,684
Website https://precigen.com
Zip 20,876